



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> :  A61F 2/44	A1	(11) International Publication Number: WO 91/16867  (43) International Publication Date: 14 November 1991 (14.11.91)
<p>(21) International Application Number: PCT/US91/03106</p> <p>(22) International Filing Date: 6 May 1991 (06.05.91)</p> <p>(30) Priority data: 520,027 7 May 1990 (07.05.90) US</p> <p>(71) Applicant: REGEN CORPORATION [US/US]; 3727 Buchanan Street, San Francisco, CA 94123 (US).</p> <p>(72) Inventor: STONE, Kevin, R. ; 133 Retiro Way, San Francisco, Ca 94123 (US).</p> <p>(74) Agents: LAPPIN, Mark, G., et al.; Lahive &amp; Cockfield, 60 State Street, Boston, MA 02109 (US).</p>		<p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p> <p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: PROSTHETIC INTERVERTEBRAL DISC</p> <div data-bbox="453 1293 1195 1633" data-label="Image"> </div> <p>(57) Abstract</p> <p>A prosthetic intervertebral disc (200) is disclosed which can be implanted in the human skeleton, and which can act as a scaffold for regrowth of intervertebral disc material. The disc (200) includes a dry, porous, volume matrix of biocompatible and bioresorbable fibers which may be interspersed with glycosaminoglycan molecules. The matrix is adapted to have <i>in vivo</i> an outer surface contour substantially the same as that of a natural intervertebral disc, whereby said matrix establishes an at least partially bioresorbable scaffold adapted for ingrowth of intervertebral fibrochondrocytes. Cross-links may be provided by a portion of the GAG molecules.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LJ	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

## PROSTHETIC INTERVERTEBRAL DISC

5 BACKGROUND OF THE DISCLOSURE

The present invention is in the field of  
implantable medical devices, and more particularly,  
is directed to devices useful as a prosthetic  
10 intervertebral disc.

The intervertebral disc acts in the spine as  
a crucial stabilizer, and as a mechanism for force  
distribution between the vertebral bodies. Without  
15 the disc, collapse of the intervertebral space occurs  
in conjunction with abnormal joint mechanics and  
premature development of arthritic changes.

Prior art methods of treating injured or  
20 diseased discs have included chemical disintegration  
procedures and surgical excision, often followed by  
bony fusion to prevent spinal collapse or  
instability. With excision, no significant

-2-

regeneration of vertebral tissue occurs. Replacement of an injured disc in an otherwise healthy spine may prevent arthritic changes and may stabilize the spinal segments. In diseased spines, replacement of the disc may reduce the progression of the disease process, and may provide pain relief.

In alternative prior art replacement approaches, discs have been replaced with prostheses composed of artificial materials. The use of purely artificial materials in the spine minimizes the possibility of an immunological response. In addition, such materials permit construction of a structure which can withstand the high and repeated loads seen by the spinal vertebral joints, and can alter the joint mechanics in beneficial ways that biological materials would not tolerate. For example, titanium, (Albrektsson et al. (1981) Acta Ortop. Scan. 52:155-170), acrylic (Cleveland (1955) Marquette Med. Rev. 20:62; Hamby et al. (1959) J. Neurosurg. 16:311), polytetrafluoroethylene-carbon fiber (Alitalo (1979) Acta Veterinaria Scandinavica Suppl. 71:1-58), and steel discs (Fenstrom (1973) Acta Chir. Scand. 4:165-186; French Patent No. 4,349,921) have been used to replace the resected disc. Each of these efforts have met with failure due to continued collapse of the disc space or erosion of the metal prosthesis into the surrounding bone.

30

A prosthetic intervertebral disc has also been constructed from resilient materials such as silicone rubber (e.g., Edeland (1985) J. Biomed Eng. 7:57-62; Schneider et al. (1974) Z. Orthop.

-3-

112:1078-1086; Urbaniak et al. (1973) J. Biomed. Mater. Res. Symposium 4:165-186). A disc has also been made from resilient plastic materials to form a bladder as disclosed in U.S. Patent Nos. 3,875,595 5 and 4,772,287; however, failure to restore full stability and normal joint biomechanics has prevented success. Porous elastomeric materials as described in U.S. Patent No. 4,349,921 have failure to recapitulate the normal vertebral body mechanics.

10

Generally, the replacement of intervertebral tissue with structures consisting of artificial materials has been unsuccessful principally because the opposing vertebral end plates of human and animal 15 joints are fragile. The end plates in the spine will not withstand abrasive interfaces nor variances from normal compliance, which evidently result from the implantation of prior art artificial discs. Additionally, joint forces are multiples of body 20 weight which, in the case of the spine, are typically over a million cycles per year. Thus far, prior art artificial discs have not been soft or durable enough, nor have they been able to be positioned securely enough to withstand such routine forces.

25

Prostheses, in general, have been devised out of at least some of the constituents of the structures which they are replacing, or out of materials not considered to be immunogenic to the 30 body. For example, Yannas et al. fashioned blood vessel grafts (U.S. Patent No. 4,350,629), synthetic epidermis (U.S. Patent No. 4,448,718), and sciatic nerve guides (WO 89/10728; Yannas (1979) Am. Chem. Soc. 16:209) out of collagen and glycosaminoglycans,

-4-

biochemical components of many body organs. By adjusting the pore size and axes of the pores and fibers comprising these structures, regrowth of natural tissue could be stimulated. Further regrowth  
5 has been advanced by seeding of the nerve guide with Schwann cells prior to implantation (see U.S. Patent No. 4,458,678). However, even with the foregoing technologies which have been applied to the reconstruction of anatomical structures other than  
10 intervertebral discs, a structure suitable as a prosthetic disc and constructed from natural materials has not yet been successfully developed.

Accordingly, it is an object of this  
15 invention to provide an intervertebral disc replacement or prosthesis.

Another object is to provide an improved disc replacement or prosthesis that does not  
20 interfere with normal vertebral segment motion as such interference could lead to a reduced range of motion or to focal concentration of force at other sites within the spinal column or instability of the opposing vertebral bodies, therefore enhancing the  
25 chances of progressive arthritic destruction.

Yet another object is to provide an improved disc replacement or prosthesis that is biomechanically able to withstand normal spinal  
30 column forces and is able to function at those loads to protect the opposing end plates and stabilize the joints.

-5-

Still another object is to provide an improved disc replacement or prosthesis which promotes regrowth of intervertebral disc material and which acts as a scaffold for fibrocartilage  
5 infiltration.

A further object is to provide an improved disc replacement or prosthesis does not evoke an immunologic reaction or aggravate other joint  
10 structures.

Still a further object is to provide an improved meniscal replacement or prosthesis which can be easily implanted by standard operative techniques.  
15

SUMMARY OF THE INVENTION

The present invention provides a biocompatible and bioresorbable structure for  
5 implantation into the spine which assumes the form and role of an intervertebral disc. This matrix may promote regrowth of intervertebral fibrochondrocytes and provides a scaffold for the regenerating intervertebral disc tissue.

10

The prosthetic disc is composed of a dry, porous, volume matrix of biocompatible and bioresorbable fibers. The matrix is adapted to have  
15 in vivo an outer surface contour substantially the same as that of a natural intervertebral disc. A portion of the fibers may be cross-linked.

The fibers include a natural fiber or an analog of a natural fiber such as a biosynthetic  
20 analog, or a synthetic fiber, or mixtures thereof. A biosynthetic fiber is one which may be produced by recombinant DNA technology including the transfection of an appropriate host cell capable of protein expression with a gene encoding, for example, a  
25 recombinant protein such as collagen. A synthetic fiber is one which may be produced by chemical methods such as, automated peptide synthesis. In one preferred embodiment of the invention, the fibers of the matrix are polymers of, for example, natural  
30 molecules such as those obtained from animal or human tissue. Natural fibers useful for the same purpose preferably include collagen, elastin, reticulin, analogs thereof, and mixtures thereof.

-7-

In some forms of the invention, the fibers may be randomly orientated throughout the matrix, or may be ordered at specified regions. Alternatively, the fibers may assume substantially circumferentially  
5 extending or substantially radially extending orientations throughout the prosthetic disc.

The matrix may also include glycosaminoglycan molecules (GAGs) interspersed with  
10 the fibers. GAGs are mucopolysaccharide molecules which provide lubrication and may be included in cross-links for the prosthetic disc. In one preferred aspect of the invention, GAGs such as chondroitin 4-sulfate, chondroitin 6-sulfate, keratin  
15 sulfate, dermatan sulfate, heparan-sulfate, heparin, hyaluronic acid, and mixtures thereof form a component of the disc. The GAGs may be uniformly dispersed throughout the prosthetic disc as individual molecules, or may be present in varying  
20 amounts in different regions of the structure.

In various forms of the invention, GAGs may directly participate in covalent cross-linking with the fibers, or may interact with the fibers  
25 mechanically in the form of entanglement or through interlocking mechanisms, thereby forming various stable fiber-GAG complexes.

The matrix may include about 75-100% natural  
30 and/or synthetic fibers and about 0-25% GAGs by dry weight, the proportions of which may be constant throughout the structure or may be variable.

-8-

In a preferred embodiment of the invention, the matrix has a density of about 0.07 to 0.50 g matrix/cm<sup>3</sup>, where "g matrix/cm<sup>3</sup>" is a unit connoting the number of grams in a cubic centimeter of the matrix. In addition, the matrix may have an interfibrillary and intrafibrillary space of about 2 to 25 cm<sup>3</sup>/g matrix.

In another form of the invention, the prosthetic disc may further include a mesh composed of a bioresorbable, biocompatible material which is attached to lateral portions of the outer surface of the matrix. The mesh aids in the successful implantation of the prosthetic intervertebral disc into the intervertebral spaces by providing a temporary anchoring mechanism.

The present invention also includes a method of regenerating intervertebral disc tissue in vivo. This method includes fabricating a prosthetic intervertebral disc of the type described above, and implanting it into the spine by surgical procedures. The presence of the prosthetic disc stimulates disc tissue growth.

25

Further, the invention includes a method for fabricating a prosthetic intervertebral disc of the type described above. Generally, the method includes placing a plurality of fibers or fibers and GAGs into a mold having a shape useful for spine function, subjecting the fibers (and GAGs) in the mold to two cycles of freezing and thawing, contacting the fibers or the fibers and GAGs with a chemical cross-linking reagent such that the fibers then assume the shape of

-9-

the mold, and lyophilizing the resulting structure to obtain a dry, porous, volume matrix.

The fibers may be laid down in a  
5 circumferential orientation by rotating the mold as they are placed therein. Alternatively, the fibers in the mold may be compressed with a rotating piston. Radial orientation of the fibers is produced by manually painting the fibers in a linear, radially  
10 directed fashion.

Specific densities and pore sizes may be obtained in various regions of the matrix by compressing the fibers or fibers and GAGs in the mold  
15 prior to the second freeze-thaw cycle, and subsequent to the chemical cross-linking step. This may be accomplished by applying pressure to a specific region of the matrix with a piston of a predetermined shape.

20

In a preferred aspect of the invention, the cross-linking step is performed using chemical agents which form intramolecular and intermolecular cross-links. Useful chemical agents include, for  
25 example, glutaraldehyde, formaldehyde, biocompatible bifunctional aldehydes, carbodiimides, hexamethylene diisocyanate, bis-ionidates, glyoxal, polyglycerol polyglycidyl ether, glyoxal, and mixtures thereof. Particularly useful cross-linking agents are 1-ethyl,  
30 3-(3-dimethylaminopropyl), polyglycerol polyglycidyl ether, acyl azide, and glutaraldehyde.

In other aspects of the invention, an additional cross-linking step is performed by

-10-

lyophilizing the chemically cross-linked disc and then subjecting it to dehydrothermal cross-linking procedures.

5           The invention will next be described in connection with certain illustrated embodiments. However, it should be clear that various modifications, additions, and deletions can be made without departing from the spirit or scope of the  
10 invention.

-11-

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects of this invention, the various features thereof, as well as 5 the invention, itself, may be more fully understood from the following description, when read together with the accompanying drawings in which:

FIG. 1 is a simplified diagrammatic 10 representation of the normal positioning of an intervertebral disc in native position in the human spine;

FIG. 2 shows a perspective view of an 15 exemplary prosthetic intervertebral disc in accordance with the present invention;

FIG. 3 shows a sectional view along line 3-3 20 of the prosthetic intervertebral disc of FIG. 2;

FIG. 4 shows a perspective view of another exemplary prosthetic intervertebral disc;

FIG. 5A shows a perspective view of another 25 exemplary prosthetic intervertebral disc including a mesh member; and FIG. 5B shows a sectional view along line 5B-5B of the prosthetic disc of FIG 5A;

FIG. 6 shows in section an exemplary mold 30 for constructing a prosthetic intervertebral disc; and

FIG. 7 shows in section an alternative mold for constructing a prosthetic intervertebral disc.

-12-

DESCRIPTION OF THE INVENTION

It has been discovered that a prosthetic intervertebral disc fabricated from biocompatible and bioresorbable fibers can be surgically implanted into the intervertebral space so as to provide normal joint motion and strength. This prosthetic intervertebral disc also acts as a scaffold for regenerating disc tissue whose ingrowth is encouraged by the physical characteristics of the implanted device. Following implantation, tissue ingrowth, regeneration, and finally resorption of the scaffold, natural intervertebratal tissue remains.

FIG. 1 shows the normal positioning of an intervertebral disc 100 in the human intervertebral space 110 between the vertebral bodies 120 and 130. An exemplary prosthetic intervertebral disc 200 is shown in FIG. 2. The disc 200 is a generally porous, dry volume matrix which extends circumferentially in about a central axis 10. As used herein, the term "volume matrix" refers to a porous array characterized by relatively comparable (but not necessarily equal) outer dimensions in three orthogonal directions (as contrasted with a sheet matrix which would have relatively comparable dimensions in two orthogonal directions but relatively small dimensions in a third orthogonal direction).

In the preferred form, prior to implantation, the prosthetic intervertebral disc 200 has the shape of a cylindrical pad, extending circumferentially about the axis 10, and comprising a

-13-

relatively high compliance central region 12 disposed about a relatively low compliance peripheral region 14. In FIG. 2, the separation of regions 14 and 16 is indicated generally by broken line 17, although the transition is normally gradual. In the preferred form, the top and bottom (as shown) surfaces of disc 200 are concave so that disc 200 has maximum height A at its peripheral edge of approximately 8 mm and a maximum radial dimension C of approximately 35 mm. FIG. 3 shows a sectional view along line 3-3 of the prosthetic disc 200 shown in FIG. 2.

FIG. 4 shows an additional embodiment 220 of the present invention which is similar in composition to the prosthetic disc 200 depicted in FIG. 2. The prosthetic intervertebral disc 220 is similar to disc 200, but includes convex top and bottom surfaces and further includes a mesh member 20 extending from its lateral surface. The mesh member 20 is composed of a biocompatible, bioresorbable material. Following implantation, the mesh member 20 may be sutured to adjacent tissue to anchor the disc 220 in place. The mesh member 20 may function in this capacity until sufficient tissue ingrowth occurs to provide that function. Since the anchor function of mesh member 20 is only temporary, the mesh member 20 may be a #1 mesh screen composed of absorbable suture materials such as polyglyconate, Dexon, or polydioxane (PDS) woven into a mesh. Alternatively, nonabsorbable suture materials such as expanded polytetrafluoroethylene (PTFE) may be used.

FIGs. 5A and 5B show yet another embodiment 230 which is similar to that of FIG. 1 but having

-14-

concave top and flat bottom surfaces. Other combinations might also be used.

In alternative forms of the invention, still  
5 other shapes than full cylinders may be used. For example, it is not required that the full 360° (about axis 10) pad be used if partial disc replacement is undertaken. For angular segment type discs, the cylindrical form may subtend any angle between zero  
10 and 360 degrees about axis 10. It is however important that the matrix have characteristics so that when implanted, at least the top and bottom surfaces substantially assume the shape or contour of a natural intervertebral disc.

15

The various embodiments of the invention may have certain densities of collagen fibers and dispersions of GAG molecules and cross-links that permit accommodation of differing stress levels,  
20 rates of ingrowth, and resiliency. Differing densities may be obtained in vivo where a device having uniform density is implanted, and body loading causes non-uniform compression of the device. Alternatively, the prosthetic disc may be initially  
25 configured with non-uniform construction of a type so that the in vivo configuration provides the desired spatial densities and dispersions necessary for the desired function.

30

The prosthetic intervertebral disc may be fabricated of any biocompatible, bioresorbable fibers such as a natural material, an analog thereof or a synthetic material. The fibers are preferably polymeric in structure so that they can provide

-15-

mechanical strength, protection, and lubrication while encouraging tissue ingrowth. Such polymeric fibers include, for example, collagen, reticulin, elastin, cellulose, and biosynthetic analogs thereof. These fibers may be ordered in substantially circumferentially-extending or substantially radially-extending orientations, with the density of fibers being substantially uniform throughout the matrix. Alternatively, the matrix fibers may be unordered. In either the ordered or unordered configuration, the density of the fibers may be non-uniform. In the non-uniform configuration, relatively high densities of fibers may be established at anticipated points of high stress.

In an alternative aspect of the invention, the intrafibrillary (i.e., the space within the fiber) and interfibrillary (the space between the fibers) space is relatively high, a condition which promotes ingrowth of regenerated disc tissue. For example, the density of the intervertebral disc may be in the range of about 10-25 g matrix/cm<sup>3</sup>. Alternatively, the intrafibrillary and interfibrillary space may be relatively low, a condition which provides superior cushioning, lubrication, and mechanical support for the intervertebral space, and which retards tissue and cell ingrowth, thereby diminishing the rate of scaffold resorption (e.g., density is in the range of about 2-10 g matrix/cm<sup>3</sup>).

The temporary stability of the shape of the structure when in vivo, and the rate of disc

-16-

resorption, are both attributed to the effective cross-link formation between at least one portion of the fibers. The cross-linking reagents used with the above-noted fiber materials may be any biocompatible, bifunctional reagents which interacts with amino, carboxyl, or hydroxyl groups on a single fiber forming intramolecular cross-links, or on multiple fibers or on the fibers and the GAGs, resulting in covalent bond formation between adjacent molecules (intermolecular cross-links). Useful cross-linking reagents include aldehydes, hexamethylene diisocyanate, bisimidates, polyglycerol polyglycidyl ether, acyl azide, and carbodiimides.

15           The cross-linked device maintains a sufficient degree of hydrophilicity and elasticity which simulates the properties of the natural intervertebral disc, i.e., ability to sustain mechanical stress and to protect and lubricate articular surfaces. In addition, the structure provides an ideal environment for cell infiltration and extracellular matrix synthesis and deposition, resulting in regeneration of natural disc tissue.

25           GAGs may be dispersed throughout the fibers. Alternatively, they may act as intermolecular cross-links between fibers. These GAGs typically include at least one of the group of molecules consisting of chondroitin 4-sulfate, chondroitin 6-sulfate, keratin sulfate, dermatan sulfate, heparan sulfate, heparin, and hyaluronic acid. The dispersion of GAG cross-links is preferably uniform, but may be more concentrated at anticipated points of high stress, typically at the

-17-

peripheral region 14, and less concentrated in the central region 12 (FIG. 2). In such configurations, the GAG concentration may be in the range of about 0-25% in the distal region 14, and in the range of about 0-10% in the central region 12. However, when uniform, the dispersion of GAGs throughout the prosthetic intervertebral disc may be, for example, in the range of about 1-15%.

10 Intermolecular cross-links can also be established through a dehydrothermal process (heat and vacuum) which results in peptide bond formation between an epsilon amino group of lysine or hydroxylysine and a carboxyl group of aspartic or  
15 glutamic acid.

The cross-linked disc has a relatively high thermal stability at between about 55-85°C, and preferably at between about 65-75°C for sufficient in  
20 vivo stability. This may be achieved through manipulation of the cross-linking conditions, including reagent concentration, temperature, pH, and time (see EXAMPLE 1).

25 In a one embodiment the prosthetic intervertebral disc is constructed mainly of Type I collagen fibers without GAG cross-links. Type I collagen fibers may be obtained from the Achilles tendons of animals. However, the fibers may also be  
30 obtained from animal skin or from the skin or tendon of humans. The tissues are treated with a series of mechanical and chemical means to either totally remove the non-collagenous materials or reduce them to a minimal level. In the preferred processing

-18-

steps, the tendon or skin is mechanically disintegrated into fine pieces useful for further processing. The disintegration may be achieved by grinding the tissue at liquid nitrogen temperature, or by cutting the tissue into small pieces with a sharp knife. In certain applications, the tendons are mechanically disintegrated along the fiber direction in order to maintain the length of the fibers for mechanical strength.

10

Salt extraction of tendon at neutral pH removes a small portion of the collagen molecules that are newly synthesized and have not yet been incorporated into the stable fibrils. Salt also removes some glycoproteins and proteoglycans that are associated with collagen through electrostatic interactions. Other salts such as KCl can be used as a substitute for NaCl.

20

Lipids that are associated with the cell membranes or collagenous matrices may be removed by first extracting with detergents such as Triton X-100 (Sigma Chemical Co., St. Louis, Missouri), followed by extracting with ether-ethanol mixtures. The concentration of Triton X-100 is usually about 2-4%, but is preferably about 3%. The preferred mixture of ether-ethanol is usually at about a 1:1 ratio (v/v). The period of extraction is usually from 8 hours to 96 hours, and is preferably from about 24 to 48 hours.

30

Further extraction may be accomplished by matrix swelling conducted at two extreme pHs. Both acidic and basic swelling weakens the non-covalent intermolecular interactions, thus facilitating the

-19-

release of non-covalently attached glycoproteins, GAGs, and other non-collagenous molecules through the open pores of the collagenous matrices.

5           The swelling of the collagenous matrix at alkaline pH is performed by treating the collagen at high pH with  $\text{Ca}(\text{OH})_2$ , NaOH, or the like, for a period of about 8-96 hours. Alkali extraction in the presence of triple-helical stabilizing salts such as  
10  $(\text{CH}_3)\text{NCl}$  or  $\text{NH}_3\text{SO}_4$  reduces the potential risk of denaturation of the collagen. Alkali treatment dissociates the non-cross-linked glycoproteins and GAGs from the collagen matrices. The alkali also removes the residual lipids through saponification.

15

Acid swelling may be conducted at a low pH in the presence of acetic acid, HCl, or similar acids. Like the alkali treatment, the swelling removes non-cross-linked glycoproteins and GAGs.

20

The non-triple helical portions of the molecule (telopeptides) are involved in intermolecular cross-linking formation. They are weak antigens and are susceptible to attack by  
25 proteases such as pepsin and trypsin. Prolonged digestion with such proteases dissociates the fibrils (fibers) into individual molecules. However, if the digestion process is properly controlled such that maximal telopeptides are removed without complete  
30 dissociation, the immunogenic properties of the fibrils can be reduced to a minimal level without compromising the mechanical strength. For example, to isolate molecular collagen, the digestion of skin or tendon with pepsin is usually conducted at an

-20-

enzyme:collagen ratio of about 1:10 for about 24-96 hours at below room temperature. In comparison, fibrils may be obtained by limited pepsin digestion achieved at a ratio of about 1:100 (enzyme:collagen) 5 for about 24-96 hours at 4°C.

Collagen fibers obtained according to this methodology are then used to fabricate the prosthetic intervertebral disc of the present invention.

10 However, it must be appreciated that collagen obtained from other sources, such as biosynthetically-produced collagen or analogs thereof, may also be used in the construction of the prosthetic intervertebral disc.

15

One method of fabrication includes molding the collagen fibers into a predetermined shape using, for example, the mold forms described below in conjunction with FIGs. 6 and 7. The fibers may be 20 placed randomly in the mold, or may be oriented in specific directions to achieve a intervertebral disc having specific structure characteristics. Other components such as GAGs which may participate in the cross-linking reaction, can be mixed in with the 25 fibers in a random or non-random fashion before the structure is subjected to various cross-linking procedures including chemical methods and/or dehydrothermal methods.

30 By following the processes described in the examples set forth hereinbelow, a prosthetic intervertebral disc of the form shown in FIGs. 2 or 3 may be constructed having the characteristics listed below in TABLE 1.

35

-21-

TABLE 1

Physical Characteristics

height A = 5 - 12 mm

5 radius C = 10 - 25 mm

density = 0.07 - 0.5 g/cm<sup>3</sup>intra- and interfibrillary space = 2 - 25 cm<sup>3</sup>/g  
matrix10 Constituents

fiber content = 75 - 100%

glycosaminoglycan content = 0 - 25%

---

15 The prosthetic discs were evaluated in vivo and in vitro to determine ability to function physically, or to serve as a regeneration template for the fibrochondrocytes expected to serve as precursor cells for the subsequent fibrocartilaginous

20 matrix. These studies demonstrate that the prosthetic disc allows for, and induces fibrochondrocyte infiltration and disc regeneration through the prosthetic material.

25 The following non-limiting examples describe methods of fabrication and in vivo use of the prosthetic intervertebral disc of the present invention.

30

EXAMPLE 1

## Mold Fabrication

A mold useful for fabricating the prosthetic intervertebral disc is made of implantable stainless

-22-

steel or biocompatible plastics such as polypropylene, delrin, or combination of these materials. Exemplary molds 300 and 300' are composed of three pieces 302, 304, and 306 as shown in FIGs. 6 5 and 7.

By way of example for the disc-shaped intervertebral disc illustrated in FIGs. 5A and 5B, the mold 300 of FIG. 6 is used. Piece 302 is 10 disc-like and has a diameter substantially equal to that of the desired intervertebral disc. Piece 302 is perforated to allow liquid to pass through under pressure. The inner surface 303 of piece 302 has the desired shape of one side of the intervertebral 15 disc-to-be-formed.

Piece 304 is a hollow cylinder which has the same inner dimension as piece 302. Piece 306 is a cylindrical piston which has an outer diameter 20 slightly less than the inner diameter of piece 304. The "top", or crown, surface 308 of piston 306 has the desired shape of one side of the intervertebral disc-to-be-formed.

25 For an intervertebral disc having flat top and bottom surfaces, the mold 500 of FIG. 7 is used where pieces 502 and 504 are the same as pieces 302 and 304 in FIG. 6, and piece 506 is similar to piece 306 in FIG. 6 but has a flat crown surface 508.

30

During fabrication of the prosthetic disc 230, mold piece 302 is first assembled within piece 304, as shown in FIG. 6. The constituent fibers (in a fluid) are placed against the surface 303 of piece

-23-

302. The crown surface 308 of piston 306 is then driven toward surface 303 along a compression axis until the fibers are compressed, the fluid is driven out through piece 302, and the desired axial dimension of the compressed fiber array is attained. The mold is then frozen in preparation for cross-linking.

#### EXAMPLE 2

##### 10 Preparation of Purified Type I Collagen

Bovine, porcine, or sheep Achilles tendon is obtained from USDA-approved slaughter houses. The preferred age of the animals is between 12 - 18 months. The tissue is kept cold during the purification process except where specified to minimize bacteria contamination and tissue degradation.

20 The adhering tissues of carefully selected tendons are first scrapped off mechanically. The tendons are then minced or cut into fine pieces and washed in excess quantities (about 10 volumes) of cold water to remove residual blood proteins and 25 water soluble materials.

The washed tendons are extracted in ten volumes of 5% NaCl, 0.01 M Tris, pH 7.4, for 24 (+/- 4) hours to remove salt soluble materials. The 30 salt-extracted tendons are repeatedly washed in about 10 volumes of water to remove the salt.

To extract lipid, the material is extracted in 3% Triton X-100 for 24 (+/- 2) hours. The

-24-

detergent is removed by extensive washing with water. The material is then extracted in 3-4 volumes of ether-ethanol (1:1 vol/vol) for 24 (+/- 2) hours to further minimize the lipid content. The lipid  
5 extracted material is extensively washed in water to remove the ether and ethanol.

The material is then subjected to two extreme pH extractions to remove non-collagenous  
10 materials. Alkaline extraction is conducted with 3-4 volumes of 0.2 M NaOH at pH 12.5 - 13.5 at room temperature in the presence of 1.0 M (CH<sub>3</sub>)NCl for 24 (+/- 2) hours with mild agitation.

15 Following alkaline extraction, the pH is neutralized with HCl, and the material is washed with water. The pH is then adjusted to 2.5 - 3.0 by adding concentrated acetic acid to a final concentration of 0.5 M. The acid extraction is  
20 continued for 24 (+/- 2) hours with agitation.

The acid swollen tendon is then subjected to a limited proteolytic digestion with pepsin (enzyme:collagen = 1:100) for 24 (+/-) 2 hours. The  
25 pepsin and resulting telopeptides are removed through dialysis.

The swollen fibrillar material is then coacervated by adjusting the pH to its isoionic point  
30 with 1 M NaOH or HCl or by adjusting the ionic strength to 0.7 with NaCl. The aggregated collagen fibers are harvested by filtration, and the filtered material extensively washed with cold phosphate

-25-

buffered saline solution. The highly purified type I collagen may be stored at -20 to -40°C until used.

### EXAMPLE 3

5

#### Device I Fabrication

A) The collagen content of the highly purified type I collagen fibrils from EXAMPLE 2 is determined either by gravimetric methods or by  
10 determining the hydroxyproline content assuming a 13.5% by weight of hydroxyproline in Type I collagen. The amount of purified material needed to fabricate a given density of a prosthetic intervertebral disc device is then determined and weighed out.

15

B) A solution of fibrillar collagen is carefully fit into a mold of desired, specified dimensions (see EXAMPLE I and FIG. 6 for a description of molds). Collagen fibers are laid down  
20 in random manner or in an oriented manner. In the oriented manner, circumferential orientation of the fibers is produced by rotation of the piston about its principal axis as the material is compressed in the mold; radial orientation is produced by manual  
25 painting of the collagen fibers in a linear, radially directed fashion.

C) The fibers are frozen at -20°C, turned out of the mold, and thawed at room temperature.

30

D) The fibers are then resuspended in phosphate buffered saline, put back into the mold in the desired orientation(s), and compressed with the piston.

35

-26-

E) The compressed fibers are then refrozen at -20°C and then thawed at room temperature.

F) The resulting structure is cross-linked by soaking in a 0.2% glutaraldehyde solution, pH 7.6, for 24 (+/- 0.5) hours. Each glutaraldehyde-cross-linked prosthetic disc is subsequently rinsed repeatedly in 500 ml of phosphate buffered saline (PBS) solution pH 7.4, for 4, 8, 24 and 48 hours.

10

G) The rinsed matrix is then lyophilized.

#### EXAMPLE 4

##### Device Fabrication

15

A)-E) (same as EXAMPLE 3)

F) The structure is immersed in an aqueous solution of 0.5 M sodium nitrite, 0.3 M HCl, and NaCl (OM, 0.34 M, 1.0 M, or 1.34 M) for 3 minutes at 4°C.

20

#### EXAMPLE 5

##### Device II Fabrication

25

A)-G) (same as in EXAMPLE 3)

H) The lyophilized matrix is subjected to dehydrothermal cross-linking by vacuum and heat. The vacuum is first applied to reduce the residual water content to a minimal level. Some structural water (about 3%) may still be associated with collagen triple-helix as part of the structure stabilizing factor. The heat is increasing in steps to 110°C

30

-27-

( $\pm 5^\circ$ ), and continually applied at  $110^\circ\text{C}$  under vacuum for 24 ( $\pm 2$ ) hours.

EXAMPLE 6

5

## Device III Fabrication

A) (same as in EXAMPLE 3)

B) The collagen material is dispersed in  
10 0.01 M HCl at pH 2.0 - 2.5. Predetermined amounts of various GAGs are weighed and dissolved in water. For example, for a given density of  $0.25\text{ g/cm}^2$ , the collagen content will be 0.244 g, the hyaluronic acid content will be 0.003 g, and the chondroitin  
15 sulfate content will be 0.003 g for a 2.5% GAG content. The GAG solution is mixed in with the collagen solution and placed in the mold in the desired orientation as described in EXAMPLE 2.

20

C)-G) (same as in EXAMPLE 3)

EXAMPLE 7

## Device IV Fabrication

25

A)-C) (same as in EXAMPLE 3)

D) (same as in EXAMPLE 3 except that the fibers laid down are not compressed.

30

E)-G) (same as in EXAMPLE 3)

-28-

EXAMPLE 8

## Device V Fabrication

A)-E) (same as in EXAMPLE 3)

5

F) The molded collagen is cross-linked in 5% polyglycerol polyglycidyl ether in 50% ethanol and 0.1 M Na<sub>2</sub>CO<sub>3</sub> at pH 10.0 for 24 (+/- 2) hours. The cross-linked device is rinsed for 4, 8, 24 and 48 10 hours, each with 500 ml of PBS, pH 7.4.

G) (same as in EXAMPLE 3)

EXAMPLE 9

## Device VI Fabrication

15

A)-E) (same as in EXAMPLE 3)

F) The molded collagen is cross-linked in 20 the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (10 mg/g matrix) in 0.9% NaCl, pH 4.7 at room temperature for 24 (+/- 2) hours. The addition of carbodiimide is made every 3 - 4 hours, and the pH is adjusted to 4.7 after each addition of 25 carbodiimide.

G) (same as in EXAMPLE 3)

-29-

EXAMPLE 10

## Device VII Fabrication

A)-D) (same as in EXAMPLE 2)

5

E) For attachment purposes, a mesh of absorbable polyglyconate suture material, matched to the size of the mold, is laid in the dispersed collagen such that it protrudes from the structure's periphery to form a skirt which may extend over the vertebral body. This mesh provides both immediate attachment sites and long term fibrous ingrowth.

F)-G) (same as in EXAMPLE 2)

15

EXAMPLE 11In vitro Testing

Intervertebral discs are aseptically harvested from mature goats or dogs, trimmed of all adherent tissue, and placed into Gey's balanced saline solution. Each disc is bisected in the coronal plane and 3 mm full-thickness circular defects are made in each half. The defects are filled with a 3 mm diameter plug of one of two prototypes of a complex collagen-based matrix. The discs are placed in six well culture plates containing 6 ml of Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, sodium ascorbate, and 0.1% penicillin/streptomycin. Cultures are maintained at 37°C in a humidified atmosphere of 10% CO<sub>2</sub>/90% air, fed three times per week, and placed in fresh culture wells every week to prevent the formation of explant cell cultures. At

-30-

intervals of one, four, and six weeks after initiation of culture, three discs from each group are removed, fixed, and evaluated with serial sections and staining. New collagen and glycosaminoglycan formation is evidenced histologically using Alcian Blue and Masson's Trichrome stains.

The results demonstrate increasing cellular migration and invasion over time. There is no apparent toxicity from the material. The depth of cellular penetration into the scaffold appears to be limited by the density of the prosthetic complex.

15

EXAMPLE 12In vivo Testing

The cervical vertebral disc of a mature goat was primarily excised and surgically replaced by a prosthetic disc. The goat returned to full cage activities within a day after surgery. Serial radiographs have documented preservation of the intervertebral joint space.

25

The present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the

30

-31-

meaning and range of equivalency of the claims are  
therefore intended to be embraced therein.

What is claimed is:

5

-32-

1. A prosthetic intervertebral disc comprising a dry, porous volume matrix of biocompatible and bioresorbable fibers,  
said matrix being adapted to have in vivo an  
5 outer surface contour substantially the same as that of a natural intervertebral disc,  
whereby said matrix establishes an at least partially bioresorbable scaffold adapted for ingrowth of vertebral fibrochondrocytes.
- 10 2. The disc of claim 1 wherein said fibers comprise polymers.
3. The disc of claim 1 wherein said fibers are  
15 selected from the group consisting of natural fibers, analogs of said natural fibers, synthetic fibers, and mixtures thereof.
4. The disc of claim 3 wherein said natural  
20 polymers are selected from the group consisting of collagen, elastin, reticulin, cellulose, analogs thereof, and mixtures thereof.
5. The disc of claim 4 wherein said natural  
25 polymers comprise collagen.
6. The disc of claim 1 further comprising cross-links between at least a portion of said fibers.
- 30 7. The disc of claim 1 further comprising a plurality of glycosaminoglycan molecules interspersed with said fibers.

-33-

8. The disc of claim 7, wherein said glycosaminoglycan molecules are selected from the group consisting of chondroitin 4-sulfate, chondroitin 6-sulfate, keratin sulfate, dermatan sulfate, heparan sulfate, heparin, hyaluronic acid, and mixtures thereof.

9. The disc of claim 7 wherein at least a portion of said molecules provide cross-links between said fibers.

10. The disc of claim 7 wherein said fibers are present at a concentration of about 75-100% by dry weight, and said glycosaminoglycan molecules are present at a concentration of about 0-25% by dry weight.

11. The prosthetic disc of claim 6 wherein said cross-links are formed by a chemical cross-linking agent.

12. The prosthetic disc of claim 11 wherein said cross-linking agent is selected from the group consisting of glutaraldehyde, formaldehyde, biocompatible bifunctional aldehydes, carbodiimides, hexamethylene diisocyanate, bis-ionidates, polyglycerol polyglycidyl ether, glyoxal, acyl azide, and mixtures thereof.

13. The prosthetic disc of claim 12 wherein said cross-linking agent comprises 1-ethyl-3-(3-dimethylaminopropyl).

-34-

14. The disc of claim 1 wherein said intervertebral disc has a density of about 0.07 to 0.50 gram matrix per cubic centimeter.
- 5 15. The disc of claim 1 wherein said intervertebral disc has an intrafibrillary and interfibrillary space of about 2 - 25 cm<sup>3</sup>/g matrix.
16. The disc of claim 1 wherein said fibers are  
10 oriented in a substantially random fashion throughout said matrix.
17. The disc of claim 1 wherein said fibers are oriented in a substantially ordered fashion  
15 throughout said matrix.
18. The disc of claim 17 wherein said matrix comprises substantially circumferentially extending fibers.  
20
19. The disc of claim 17 wherein said matrix comprises substantially radially extending fibers.
20. The disc of claim 1 wherein the density of  
25 said fibers is substantially uniform throughout said matrix.
21. The disc of claim 1 wherein said fibers are oriented in a substantially ordered fashion in the  
30 region adjacent to the peripheral edge of said disc, said orientation being substantially circumferential.

-36-

said prosthetic intervertebral disc thus formed comprising a dry porous volume matrix being adapted to have in vivo an outer surface contour substantially the same as that of a natural  
5 intervertebral disc,

whereby said matrix establishes an at least partially bioresorbable scaffold adapted for ingrowth of vertebral fibrochondrocytes.

10 27. The method of claim 24 wherein said placing step comprises placing a plurality of fibers into a mold, said fibers including a natural material, an analog thereof, or a synthetic material.

15 28. The method of claim 27 wherein said analog of said natural material is a biosynthetic analog.

29. The method of claim 26 wherein said placing step further comprises placing a plurality of  
20 polymeric fibers into said mold.

30. The method of claim 26 wherein said fibers are selected from the group consisting of collagen, elastin, reticulin, cellulose, analogs thereof, and  
25 mixtures thereof.

31. The method of claim 26 wherein said placing step further comprises placing a plurality of glycosaminoglycan molecules into said mold.

30

-35-

22. The disc of claim 21 wherein said fibers are oriented in a substantially random fashion in the central region of said disc.

5 23. The disc of claim 7 wherein said glycosaminoglycan molecules are dispersed substantially uniformly throughout said matrix.

24. The disc of claim 7 wherein said  
10 glycosaminoglycan molecules are dispersed nonuniformly throughout said matrix.

25. The disc of claim 1 further comprising a mesh extending from a portion of the outer surface of  
15 said matrix, said mesh being resorbable and biocompatible.

26. A method for fabricating a prosthetic intervertebral disc comprising the steps of:

20

(a) placing a plurality of biocompatible and bioresorbable fibers into a mold, said mold having a shape that enables disc space function;

25

(b) subjecting said fibers to a first and a second cycle of freezing and thawing;

30

(c) contacting said fibers with a chemical cross-linking agent such that said fibers assume the shape of said mold; and

(d) lyophilizing said cross-linked fibers,

-37-

32. The method of claim 31 wherein said glycosaminoglycan molecules are selected from the group consisting of chondroitin 4-sulfate, chondroitin 6-sulfate, keratin sulfate, dermatan sulfate, heparin, heparan sulfate, hyaluronic acid, and mixtures thereof.

33. The method of claim 26 wherein said placing step further comprises the step of orienting said 10 fibers substantially circumferentially.

34. The method of claim 33 wherein said orienting step comprises compressing said fibers in said mold with a piston, directed along a compression 15 axis, while during said compressing step said piston is rotated with respect to said mold about said compression axis.

35. The method of claim 33 wherein said 20 orienting step comprises rotating said mold as said fibers are placed therein.

36. The method of claim 26 wherein said placing step further comprises the step of orienting said 25 fibers substantially radially.

37. The method of claim 26 further comprising the step of compressing said fibers prior to said second cycle of freezing and thawing.

30

38. The method of claim 31 further comprising the step of compressing said fibers and said GAGs prior to said second cycle of freezing and thawing.

-38-

39. The method of claim 37 wherein said compressing step comprises applying a predetermined amount of pressure to a region of said matrix with a piston, said piston having a predetermined shape.

5

40. The method of claim 26 wherein said chemical cross-linking agent is selected from the group consisting of glutaraldehyde, formaldehyde, biocompatible and bifunctional aldehydes, carbodiimides, hexamethylene diisocyanate, bisimides, polyglycerol polyglycidylether, glyoxal, acyl azide, and mixtures thereof.

41. The method of claim 26 further comprising the additional step of subjecting said lyophilized matrix to dehydrothermal cross-linking.

42. A method of regenerating intervertebral tissue in vivo comprising the steps of:

20

(a) fabricating a prosthetic intervertebral disc comprising a dry porous volume matrix of biocompatible and bioresorbable fibers, said matrix being adapted to have in vivo an outer surface contour substantially the same as that of a natural intervertebral disc, whereby said matrix establishes an at least partially bioresorbable scaffold adapted for ingrowth of vertebral fibrochondrocytes; and

25

30

-39-

(b) implanting said disc into a spine by surgical procedures,


said implanted disc stimulating regeneration  
5 of intervertebral tissue.

43. The method of claim 42 wherein said fabricating step comprises cross-linking at least a portion of said fibers.


10

44. The method of claim 42 wherein said fabricating step comprises fabricating a plurality of glycosaminoglycan molecules.


15 45. The method of claim 42 wherein said fabricating step further comprises fabricating a prosthetic intervertebral disc comprising a mesh extending from portions of the outer surface of said disc, said mesh being resorbable and biocompatible.




*FIG. 1*




**FIG. 2**




**FIG. 3**




**FIG. 4**




**FIG. 5A**



**FIG. 5B**



**FIG. 6**



**FIG. 7**

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/03106

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC (5): A61F 2/44 US.Cl.: 623/17														
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched <sup>7</sup></div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%;">Classification System</th> <th style="width: 75%;">Classification Symbols</th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">U.S.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">623/11, 16, 17, 18, 1, 66</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup></div>			Classification System	Classification Symbols	U.S.	623/11, 16, 17, 18, 1, 66								
Classification System	Classification Symbols													
U.S.	623/11, 16, 17, 18, 1, 66													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category <sup>9</sup></th> <th style="width: 60%;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 30%;">Relevant to Claim No. <sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">US, A, 4,280,954 (YANNAS ET AL.) 28 July 1981 (See entire document)</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-16,20,23-25 42-45</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">US, A, 4,801,299 (BRENDLE, ET AL.) 31 January 1989 (Column 7, lines 30-40)</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-16,20,23-25 42-45</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">US, A, 4,911,718 (LEE, ET AL.) 27 March 1990 (See figure 3)</td> <td style="text-align: center; vertical-align: top; padding: 5px;">17-19,21,22</td> </tr> </tbody> </table>			Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X	US, A, 4,280,954 (YANNAS ET AL.) 28 July 1981 (See entire document)	1-16,20,23-25 42-45	X	US, A, 4,801,299 (BRENDLE, ET AL.) 31 January 1989 (Column 7, lines 30-40)	1-16,20,23-25 42-45	X	US, A, 4,911,718 (LEE, ET AL.) 27 March 1990 (See figure 3)	17-19,21,22
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
X	US, A, 4,280,954 (YANNAS ET AL.) 28 July 1981 (See entire document)	1-16,20,23-25 42-45												
X	US, A, 4,801,299 (BRENDLE, ET AL.) 31 January 1989 (Column 7, lines 30-40)	1-16,20,23-25 42-45												
X	US, A, 4,911,718 (LEE, ET AL.) 27 March 1990 (See figure 3)	17-19,21,22												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>														
<b>IV. CERTIFICATION</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;">           Date of the Actual Completion of the International Search   <b>17 September 1991</b> </td> <td style="width: 50%; padding: 5px;">           Date of Mailing of this International Search Report   <b>10 OCT 1991</b> </td> </tr> <tr> <td style="width: 50%; padding: 5px;">           International Searching Authority   <b>ISA/US</b> </td> <td style="width: 50%; padding: 5px;">           Signature of Authorized Officer  <b>NGUYEN NGOC-HO</b> <i>Nguyen Ngoc Ho</i>  <b>INTERNATIONAL DIVISION</b>  <b>David L. Isabella</b> </td> </tr> </table>			Date of the Actual Completion of the International Search  <b>17 September 1991</b>	Date of Mailing of this International Search Report  <b>10 OCT 1991</b>	International Searching Authority  <b>ISA/US</b>	Signature of Authorized Officer <b>NGUYEN NGOC-HO</b> <i>Nguyen Ngoc Ho</i> <b>INTERNATIONAL DIVISION</b> <b>David L. Isabella</b>								
Date of the Actual Completion of the International Search  <b>17 September 1991</b>	Date of Mailing of this International Search Report  <b>10 OCT 1991</b>													
International Searching Authority  <b>ISA/US</b>	Signature of Authorized Officer <b>NGUYEN NGOC-HO</b> <i>Nguyen Ngoc Ho</i> <b>INTERNATIONAL DIVISION</b> <b>David L. Isabella</b>													